VYNE Therapeutics (NASDAQ:VYNE) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research report released on Monday morning, Benzinga reports. HC Wainwright currently has a $5.75 price objective on the stock.

VYNE Therapeutics Stock Down 2.6 %

VYNE stock opened at $2.65 on Monday. VYNE Therapeutics has a 52 week low of $1.67 and a 52 week high of $7.88. The firm has a 50-day simple moving average of $2.51 and a 200-day simple moving average of $2.59. The stock has a market capitalization of $37.37 million, a P/E ratio of -0.39 and a beta of 1.26.

VYNE Therapeutics (NASDAQ:VYNE) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.30. The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.15 million. VYNE Therapeutics had a negative return on equity of 77.46% and a negative net margin of 6,710.38%. On average, analysts expect that VYNE Therapeutics will post -1 earnings per share for the current year.

Institutional Investors Weigh In On VYNE Therapeutics

An institutional investor recently bought a new position in VYNE Therapeutics stock. Parkman Healthcare Partners LLC purchased a new position in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 696,470 shares of the company’s stock, valued at approximately $1,623,000. Parkman Healthcare Partners LLC owned about 4.99% of VYNE Therapeutics at the end of the most recent quarter. 83.78% of the stock is currently owned by institutional investors and hedge funds.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.